Drug development for obesity has been fraught with failures and false-starts, in part owing to the complex pathways that govern energy homeostasis. One strategy is to intervene in key pathways using synthetic agents that mimic the action of endogenous molecules. Decara et al. now report that elaidyl-sulfamide, a molecule based on the anorectic lipid oleoylethanolamide (OEA), reduces food intake, body weight, plasma cholesterol and markers of hepatic dysfunction in obese rats. Similar to OEA, elaidyl-sulfamide was found to act as a PPARα agonist. However, in line with the ability of OEA to negatively regulate insulin signalling, chronic elaidyl-sulfamide treatment induced insulin resistance. This study suggests that chemical modelling of OEA is a promising avenue for drug development, providing that the effects of related compounds on insulin signalling can be overcome or are found to be negligible in humans. Page 660
A PPARα agonist improves metabolic parameters in obesity
A PPARα agonist improves metabolic parameters in obesity. Dis Model Mech 1 September 2012; 5 (5): 566. doi:
Download citation file:
Advertisement
Cited by
DMM Journal Meeting 2024: Pre-clinical Modelling of Human Genetic Disease and Therapy

Registration is now open for our 2024 Journal Meeting. Rapid advances in gene editing and genetic technologies have revolutionised our ability to model human genetic disease and provided new hope for gene therapies. At this Meeting, we will present the very latest advances in modelling human genetic disease.
A new call for papers is underway

Showcase your latest research in our upcoming special issue Translating Multiscale Research in Rare Disease, coordinated by DMM Editors Monica Justice, Karen Liu and Monkol Lek, and Guest Editor Kate Rauen. The deadline for submitting articles to the special issue is Monday 6 November 2023.
Moving towards heart success – Disease Models & Mechanisms Special Issue

DMM's most recent special issue compiles articles that aim to move heart failure to heart success by fundamentally addressing the roots of failure to identify curative strategies.
Adult zebrafish as advanced models of human disease

Editor-in-Chief Liz Patton and Editorial Board member Rich White discuss the unique advantages of adult zebrafish for studying human disease biology. Read the Open Access Editorial here.
The Forest of Biologists

The Forest of Biologists is a biodiversity initiative created by The Company of Biologists, with support from the Woodland Trust. For every Research and Review article published in Disease Models & Mechanisms a native tree is planted in a UK forest. In addition to this we are protecting and restoring ancient woodland and are dedicating these trees to our peer reviewers. Visit our virtual forest to learn more.
Other journals from
The Company of Biologists